{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:47:57Z","timestamp":1791445677935,"version":"4.3.3"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"name":"PROGRES Q 25, Ministry of Education, Czech Republic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.2215\/cjn.15861219","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T16:47:19Z","timestamp":1590770839000},"page":"1519-1521","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis"],"prefix":"10.2215","volume":"15","author":[{"given":"Vladimir","family":"Tesar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenka","family":"Hruskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2215\/CJN.00100114","article-title":"Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis","volume":"9","author":"Walsh","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/rheumatology\/kex281","article-title":"Long term azathioprine maintenance therapy in ANCA-associated vasculitis: Combined results of long-term follow-up data","volume":"56","author":"de Joode","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/rheumatology\/kez148","article-title":"Subclassifying ANCA-associated vasculitis: A unifying view of disease spectrum","volume":"58","author":"Mahr","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.15861219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:50Z","timestamp":1786369190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.15861219"}},"subtitle":["Should Type of ANCA Guide the Treatment?"],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.15861219","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]}}}